MX2020003427A - Agentes terapeuticos para enfermedades neurodegenerativas. - Google Patents
Agentes terapeuticos para enfermedades neurodegenerativas.Info
- Publication number
- MX2020003427A MX2020003427A MX2020003427A MX2020003427A MX2020003427A MX 2020003427 A MX2020003427 A MX 2020003427A MX 2020003427 A MX2020003427 A MX 2020003427A MX 2020003427 A MX2020003427 A MX 2020003427A MX 2020003427 A MX2020003427 A MX 2020003427A
- Authority
- MX
- Mexico
- Prior art keywords
- neurodegenerative diseases
- therapeutic agents
- leucine
- acetyl
- present disclosure
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 abstract 1
- 229960000669 acetylleucine Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente descripción se proporciona para tratar enfermedades neurodegenerativas que comprende administrar leucina, acetil-leucina o una sal farmacéuticamente aceptable de las mismas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574137P | 2017-10-18 | 2017-10-18 | |
| PCT/US2018/018420 WO2019078915A1 (en) | 2017-10-18 | 2018-02-15 | THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003427A true MX2020003427A (es) | 2020-09-14 |
Family
ID=66174216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003427A MX2020003427A (es) | 2017-10-18 | 2018-02-15 | Agentes terapeuticos para enfermedades neurodegenerativas. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11793782B2 (es) |
| EP (1) | EP3697399A1 (es) |
| JP (1) | JP2021500342A (es) |
| KR (1) | KR102549684B1 (es) |
| CN (1) | CN111542314B (es) |
| AU (1) | AU2018351709B2 (es) |
| BR (1) | BR112020007657A2 (es) |
| CA (1) | CA3079194A1 (es) |
| IL (1) | IL273929A (es) |
| MA (1) | MA50383A (es) |
| MX (1) | MX2020003427A (es) |
| RU (1) | RU2763425C2 (es) |
| SG (1) | SG11202003390UA (es) |
| WO (1) | WO2019078915A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| US11660279B2 (en) | 2018-02-15 | 2023-05-30 | Intrabio Limited | Therapeutic agents for treating restless leg syndrome |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1780616B (zh) * | 2003-03-06 | 2010-05-12 | 细胞基因公司 | 治疗中枢神经***疾病的选择性细胞因子抑制药物 |
| RU2377234C2 (ru) * | 2003-09-17 | 2009-12-27 | Ксенопорт, Инк. | Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк |
| KR101730290B1 (ko) * | 2007-05-11 | 2017-04-25 | 토마스 제퍼슨 유니버시티 | 신경변성 질환 및 장애의 치료 및 예방 방법 |
| EP2289886A1 (en) * | 2009-08-31 | 2011-03-02 | Institut d'Investigacions Biomédiques August PI I Sunyer | Peptoid agonists of nerve growth factor and their use as medicaments |
| US8202525B2 (en) * | 2009-12-22 | 2012-06-19 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| RU2626514C2 (ru) | 2010-06-25 | 2017-07-28 | Шир Хьюман Дженетик Терапис, Инк. | Доставка к цнс лечебных агентов |
| WO2015129527A1 (ja) * | 2014-02-27 | 2015-09-03 | 株式会社メドレックス | プラミペキソールを含有する神経変性疾患の治療用貼付剤 |
| SG11201901063SA (en) * | 2016-08-11 | 2019-03-28 | Intrabio Ltd | Therapeutic agents for neurodegenerative diseases |
-
2018
- 2018-02-15 KR KR1020207014143A patent/KR102549684B1/ko active IP Right Grant
- 2018-02-15 MA MA050383A patent/MA50383A/fr unknown
- 2018-02-15 MX MX2020003427A patent/MX2020003427A/es unknown
- 2018-02-15 SG SG11202003390UA patent/SG11202003390UA/en unknown
- 2018-02-15 AU AU2018351709A patent/AU2018351709B2/en active Active
- 2018-02-15 US US16/756,948 patent/US11793782B2/en active Active
- 2018-02-15 RU RU2020115710A patent/RU2763425C2/ru active
- 2018-02-15 WO PCT/US2018/018420 patent/WO2019078915A1/en unknown
- 2018-02-15 CN CN201880081672.6A patent/CN111542314B/zh active Active
- 2018-02-15 CA CA3079194A patent/CA3079194A1/en active Pending
- 2018-02-15 BR BR112020007657-0A patent/BR112020007657A2/pt unknown
- 2018-02-15 EP EP18708286.2A patent/EP3697399A1/en active Pending
- 2018-02-15 JP JP2020521938A patent/JP2021500342A/ja active Pending
-
2020
- 2020-04-12 IL IL273929A patent/IL273929A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020115710A3 (es) | 2021-11-18 |
| AU2018351709B2 (en) | 2024-01-04 |
| KR20200074170A (ko) | 2020-06-24 |
| WO2019078915A1 (en) | 2019-04-25 |
| CA3079194A1 (en) | 2019-04-25 |
| JP2021500342A (ja) | 2021-01-07 |
| RU2763425C2 (ru) | 2021-12-29 |
| MA50383A (fr) | 2020-08-26 |
| KR102549684B1 (ko) | 2023-06-29 |
| US11793782B2 (en) | 2023-10-24 |
| BR112020007657A2 (pt) | 2020-09-29 |
| CN111542314A (zh) | 2020-08-14 |
| SG11202003390UA (en) | 2020-05-28 |
| AU2018351709A1 (en) | 2020-05-07 |
| US20210196659A1 (en) | 2021-07-01 |
| RU2020115710A (ru) | 2021-11-18 |
| IL273929A (en) | 2020-05-31 |
| CN111542314B (zh) | 2023-11-24 |
| EP3697399A1 (en) | 2020-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006901A (es) | Agentes terapeuticos para enfermedades neurodegenerativas. | |
| EP3399972A4 (en) | LOW DOSE THERAPEUTIC TREATMENT | |
| UA122346C2 (uk) | ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ | |
| MX2016016593A (es) | Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos. | |
| PH12017500493A1 (en) | Combination therapy | |
| MX2017003819A (es) | Macrociclos peptidomimeticos y formulaciones de los mismos. | |
| PH12018502109A1 (en) | Medicine obtained by combining fxr agonist and arb | |
| EP3970712A3 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
| MX2017011206A (es) | Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer. | |
| MX2019006721A (es) | Tratamiento para la colangitis biliar primaria. | |
| IL273169A (en) | A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases | |
| PH12019502197A1 (en) | Macrocyclic compound and uses thereof | |
| MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
| PH12019501955A1 (en) | Tri-cycle compound and applications thereof | |
| MX2019002369A (es) | Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial. | |
| MX2019002901A (es) | Tratamiento de esclerosis multiple con chs-131. | |
| MX2020003427A (es) | Agentes terapeuticos para enfermedades neurodegenerativas. | |
| PH12021550452A1 (en) | Methods of treating mycobacterial infections using tetracycline compounds | |
| MX2019008338A (es) | Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco. | |
| PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
| WO2015142865A3 (en) | Metakaryocidal treatments | |
| EP3862012A4 (en) | THERAPEUTIC FOR NEURODEGENERATIVE DISEASES | |
| MX2019014784A (es) | Tratamiento para la migra?a. | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
| MX2020008504A (es) | Agentes terapeuticos para tratar el sindrome de piernas inquietas. |